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ABSTRACT Osteomyelitis can result from the direct inoculation of pathogens into bone during injury or
surgery or from spread via the bloodstream, a condition called hematogenous osteomyelitis (HOM).
HOM disproportionally affects children, and more than half of cases are caused by Staphylococcus
aureus. Laboratory models of osteomyelitis mostly utilize direct injection of bacteria into the bone or
implantation of foreign material and therefore do not directly interrogate the pathogenesis of pediatric
hematogenous osteomyelitis. In this study, we inoculated mice intravenously and characterized the
resultant musculoskeletal infections using two strains isolated from adults (USA300-LAC and NRS384)
and five new methicillin-resistant S. aureus isolates from pediatric osteomyelitis patients. All strains
were capable of creating stable infections over 5 weeks, although the incidence varied. Micro-computed
tomography (microCT) analysis demonstrated decreases in the trabecular bone volume fraction but
little effect on bone cortices. Histological assessment revealed differences in the precise focus of
musculoskeletal infection, with various mixtures of bone-centered osteomyelitis and joint-centered
septic arthritis. Whole-genome sequencing of three new isolates demonstrated distinct strains, two
within the USA300 lineage and one USA100 isolate. Interestingly, this USA100 isolate showed a
distinct predilection for septic arthritis compared to the other isolates tested, including NRS384 and
LAC, which more frequently led to osteomyelitis or mixed bone and joint infections. Collectively, these
data outline the feasibility of using pediatric osteomyelitis clinical isolates to study the pathogenesis of

HOM in murine models and lay the groundwork for future studies investigating strain-dependent
differences in musculoskeletal infection.
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I

nfectious osteomyelitis (OM) is commonly bacterial in origin, with Staphylococcus aureus being
the pathogen most frequently identified (1). Hematogenous osteomyelitis (HOM), initiated via
the seeding of bacteria through the bloodstream, predominantly affects children, with 85% of
cases occurring in children under 17 years of age (1–4). HOM in children is not rare, with a
reported incidence between 1 in 1,000 and 1 in 20,000 (5–7), but it is notoriously difficult to treat,
often requiring prolonged antibiotics and surgical debridement. The recurrence rate may be as
high as 9% (7–10), and this problematic event can extend into adulthood (11). Typically, HOM
involves the metaphysis of long bones, predominantly the distal femur or proximal tibia (12). A
main concern with pediatric HOM is the development of chronic infection. This can cause
pathological bone changes leading to fractures, dislocations, and devitalized bone segments
known as sequestra (12). HOM infections can also spread to an adjacent joint, causing septic
arthritis (SA), or systemically, leading to potentially lethal sepsis (12, 13). Additionally,
antimicrobial-resistant strains, particularly methicillin-resistant S. aureus (MRSA), are highly
prevalent in both health care and community settings (14).
Despite significant clinical challenges, studies of the specific mechanisms underlying HOM
development and progression have been relatively limited. This is partly because most animal
models recapitulate cases of bone infection related to orthopedic surgery and involve
manipulations of the bone, including the creation of cortical defects or the placement of hardware
into the bone (15–20). One study utilized the hematogenous route but relied upon the implantation
of metal into the femur before the injection of bacteria (19). Although HOM has been modeled in
mice without prior manipulation (21–24), characterization of bone changes and comparisons
among strains have been limited.
In addition to two previously established community-acquired USA300 strains isolated from
adults (16, 25, 26), we utilized several new clinical isolates of S. aureus from pediatric HOM
patients. To mimic the bone microenvironment in children, the population in which HOM is most
prevalent, we intravenously inoculated young (6-week-old), actively growing mice. The generation
of stably bioluminescent bacteria allowed real-time, longitudinal assessment of infection
localization and progression in vivo while preserving the bone for downstream analysis by microcomputed tomography (microCT) and histology. We compared measures of pathogenicity between
these isolates, including the incidence of hindlimb infection, propensity toward developing bonecentered HOM or joint-centered SA, subsequent bone loss, cytotoxicity toward host cells, and
intracellular proliferation. We also performed genomic sequence analysis of 3 of these isolates,

discovering significant genetic differences among the clinical isolates. Taken together, these
studies provide a robust platform for the analysis of host-pathogen interactions in HOM.
RESULTS
Modeling hematogenous osteomyelitis using NRS384 and LAC. We first established HOM
with two USA300 strains of S. aureus previously made spontaneously bioluminescent by us and
another group, via the stable integration of a plasmid bearing the lux operon (27, 28), allowing the
tracking of infection over time in vivo. We injected 2.5 × 106 CFU of NRS384 or LAC in phosphatebuffered saline (PBS) into the tail vein of wild-type C57BL/6-albino mice at 6 weeks of age, a
period of rapid growth. With this inoculum, we did not observe any instances of lethal sepsis or
other complications requiring euthanasia prior to 4 weeks after infection with either strain (see Fig.
S1 in the supplemental material). Bioluminescence imaging (BLI) was performed weekly for 5
weeks. With both USA300 strains, distinct foci of signals were frequently seen in hindlimbs as well
as bladder, likely indicative of bacteria being shed from the kidneys (Fig. 1A and B). Foci of signals
were also observed in the rostrum and occasionally the forelimb. Based on this distribution of
bone-centric signals, regions of interest were drawn over the hindlimbs, also referred to as legs
(as in Fig. S2), allowing quantitation over time (Fig. 1C and D). We found no appreciable
differences between signal intensities from either strain or the two cohorts of mice injected on
different days (trial 1 and trial 2), and the signal values stabilized at around the 2-week time point,
suggesting the establishment of chronic infection. Because of this BLI signal stabilization, the trial
2 LAC-injected mice were harvested at 2 weeks. Next, we used all the BLI values acquired to
devise a BLI positivity threshold to stratify actively infected BLI-positive (BLI+) legs from BLInegative (BLI−) legs for later analyses. This threshold was set at 70,000 photons/s because legs
under this value consistently had no foci of BLI signals over the 5-week course of infection,
excluding “bleed” from strong bladder signals (as in Fig. S2B, right leg), while the baseline signal
for autoluminescence was around 35,000 photons/s. Furthermore, no legs that reached this
threshold subsequently fell below it. Interestingly, we observed that the cohorts injected with
NRS384 had a markedly higher percentage of mice that developed a hindlimb infection, as
detected by BLI, than in LAC-injected cohorts (80% versus 35% cumulative incidence).

FIG 1 Longitudinal tracking of NRS384 and LAC hematogenous osteomyelitis. (A and B) In vivo bioluminescence
imaging (BLI) of two representative mice (top and bottom rows), performed weekly for 5 weeks, after injection with
NRS384 (A) or LAC (B) strains of S. aureus. Arrows highlight BLI foci. (C and D) Quantification of NRS384 (C) and
LAC (D) BLI signals measured in each hindlimb (2 data points per mouse) for two separate trials over the 5 weeks

postinjection (n = 10 mice per trial) (the BLI threshold is set at 70,000 photons/second). LAC trial 2 purposely
terminated at 2 weeks postinjection.

Since most BLI signals for NRS384-injected mice appeared to be proximal to the knee joint
(Fig. 1A, arrows), femurs were assessed by microCT. Reconstructions indicated that the bone
disruption is predominantly localized to the trabecular compartment (Fig. S3A). Quantification of
the trabecular bone volume fraction (ratio of the bone volume to the total volume [BV/TV]) in the
femur demonstrated significant decreases from both BLI− and BLI+ legs compared to those from
noninjected control mice (Fig. 2A). While no statistical difference was found between BLI− and
BLI+ legs of these NRS384-injected mice, extreme destruction of trabecular bone (BV/TV ratio
below 0.1) was seen only in BLI+ legs. Interestingly, the BLI signal from LAC-injected mice
appeared more distal than in NRS384-injected mice (Fig. 1B, arrows), so we measured the
trabecular bone volumes from both femurs and tibias. The femoral BV/TV ratio in LAC-injected
mice was lower than that in control mice, but there was no difference in BV/TV ratios between
BLI− and BLI+ legs, nor was there a difference between femurs harvested at 2 and 5 weeks (Fig.
2B; Fig. S3B). However, the trabecular bone volumes in tibias of BLI+ legs were decreased
compared to those in tibias from legs that were BLI− in LAC-injected mice, reaching statistical
significance only at 5 weeks postinjection (Fig. 2C; Fig. S3B). Overall, we were able to induce
consistent hindlimb HOM with both the NRS384 and LAC strains using our intravenous injection
model.

FIG 2 Trabecular bone volume fractions from NRS384- and LAC-injected mice. (A and B) Trabecular bone
volume/total volume (BV/TV) ratio measured by micro-computed tomography (microCT) in femurs from noninjected
control mice and NRS384 (A)- and LAC (B)-injected mice. The control group (age, sex, and strain matched) is the
same in panels A and B. (C) Tibial trabecular BV/TV ratio from LAC-injected mice measured at 2 or 5 weeks
postinjection. The BLI− or BLI+ designation is based on the threshold in the legend of Fig. 1. P values were
calculated by one-way ANOVA with Tukey’s multiple-comparison post hoc test.

Characterizing HOM caused by S. aureus clinical isolates from children with OM. To
expand the clinical significance of this model to pediatric HOM, we acquired five isolates of
methicillin-resistant S. aureus (MRSA) from pediatric patients with HOM (Table 1). In order to
employ these isolates for BLI during HOM in mice, we utilized the same stable chromosomal
integration system for the lux operon used previously for NRS384 (27). To confirm that the
bioluminescence of each isolate corresponds to an equivalent bacterial burden, we measured the
BLI signal from in vitro serial dilutions of each isolate and correlated that with CFU enumerated
from the same dilutions (Fig. S4). In liquid culture, the growth of TI2 and TI5 was minimally
delayed (Fig. S5A). Growth curves of the lux isolates were slightly accelerated compared to their
respective parental isolates, suggesting that the lux operon did not inhibit the growth kinetics of
any of the isolates (Fig. S5B). Tail vein injection of 2.5 × 106 CFU of all 5 isolates led to
reproducible infections with localization over hindlimbs (Fig. 3A; Fig. S6A and B) and limited
lethality (Fig. S6C), comparable to those of NRS384 and LAC (Fig. S1). Interestingly, we
discovered differences between the isolates in the rates at which they led to hindlimb infections in
these mice, using our previously established BLI positivity threshold (Fig. 3B). Two of the isolates,
TI1 and TI3, had a very high incidence of infection in at least one hindlimb, 72% and 89%,
respectively, comparable to that of NRS384. However, TI2 had a much lower rate of infection,
25%, over the 5-week time course, similar to the incidence with LAC. The other two strains, TI4
and TI5, had infection rates between these extremes, 46% and 67%, respectively. For subsequent
analyses, we focused primarily on TI3 and TI1, with the highest incidences of hindlimb infection,
as well as TI2, with the lowest.

FIG 3 Characterization of hematogenous osteomyelitis using clinical isolates of S. aureus. (A) In vivo
bioluminescence imaging (BLI) of three representative mice for each isolate at 5 weeks postinjection. (B)
Quantification of the BLI signal measured in the hindlimb of each injected mouse depicted over the 5 weeks
postinjection (n = 20 per isolate) (the BLI threshold is 70,000 photons/s). (C) Enumerated bacterial burdens from the
indicated organs, as measured by a CFU assay at 3 weeks postinjection. BLI+ and BLI− legs are the counts from
femurs from legs with BLI signals higher and lower than 70,000 photons/s, respectively (n = 7 mice from a separate
cohort from those in panels A and B injected with TI3) (each dot represents one leg). (D) Correlation of the bacterial
burden (CFU) from panel C with the BLI signal of the corresponding leg. Open and closed dots correspond to the
BLI+/− designations in panel C.

To further validate BLI as a proxy for bacterial load in vivo, we measured CFU obtained from
homogenized femurs, along with the heart, liver, and kidneys, from mice injected with TI3 2 weeks
previously (Fig. 3C). High levels (∼5 × 106 CFU/organ) of bacteria were found in the kidneys and
hindlimb bones from BLI+ legs, as expected, and the correlation between CFU and the
corresponding BLI signal in hindlimbs was strong (Fig. 3D).
We next compared the trabecular BV/TV ratios from mice injected with these three clinical
isolates, focusing on femurs because BLI signals were primarily proximal to the knee. As with the
NRS384-injected mice, we found a significant decrease in all the bone volumes of femurs from
mice injected with each clinical isolate compared to femurs of noninjected mice. However, with
these mice, we also found a consistent decrease in the bone volume fractions of femurs from BLI+
legs compared to BLI− legs (Fig. 4A). Finally, we pooled the data from the BLI+ and BLI− legs of all
three clinical isolates and found a weak but statistically significant correlation between the BLI
signal and the BV/TV ratio from the corresponding femur (Fig. 4B). These data further validated
our utilization of BLI to track infection incidence and location.

FIG 4 Reduced bone volumes are associated with the local bacterial burden with HOM induced by clinical isolates.
(A) Trabecular BV/TV ratio measured by microCT of femurs from noninjected control mice (same cohort as in Fig.
2) and mice injected with either TI1, TI2, or TI3. Classification as BLI− or BLI+ legs was determined by the threshold
in the Fig. 3 legend. *, P ≤ 0.0014 for the control versus all other groups as calculated by one-way ANOVA with
Tukey’s multiple-comparison post hoc test. P values between BLI− and BLI+ BV/TV ratios within each strain were
calculated by Student’s t test. (B) Correlation of the BV/TV data from panel A with the BLI signal from the
corresponding leg. Dot coding corresponds to the coding in panel A.

Osteomyelitis and septic arthritis result from hematogenous inoculation with S. aureus
strains. We next examined hindlimbs by standard histology 5 weeks after infection, finding various
combinations of bone and joint involvement. Figure 5 depicts representative histological images of
three separate samples of the distal femur and knee joint (one per column) from infections with
NRS384 and LAC and three pediatric isolates (TI1, TI2, and TI3). Some samples (Fig. 5D, H, M,
and N) appear to have infections localized entirely within the bone and medullary cavity, indicative
of OM. Other samples (Fig. 5B, I, K, and L) show clear infection and inflammation within the joint
space (black arrows), while the femur and tibia remain normal, demonstrating septic arthritis (SA).
Finally, there are samples (Fig. 5A, C, E to G, and O) where the infection is present both in the
bone and joint (OM+SA). However, in the latter samples, some infections seem to extend into the
joint from severe bone involvement (Fig. 5A, C, and F, black arrowheads), while others seem to
represent a joint-centered infection focally extending into the bone (Fig. 5J, black arrowheads). In

all cases of OM infections, there is significant loss of trabecular bone, and in extreme cases, there
is disruption of the growth plate as well (Fig. 5C to E, J, M, and O, #). We did not observe
extension through the cortical bone to the periosteal surface in affected femurs. The various
patterns of bone and joint involvement for each strain were then enumerated (Table 2). NRS384
and TI1 produced mixtures of bone-centered OM and joint-centered SA infections. However, LAC
and TI3 predominantly produced OM, with no case of SA that was not coincidental with OM. TI2
predominantly produced SA, with only one case of OM that was not associated with SA.
Interestingly, LAC produced OM lesions in the tibias but not the femurs of 6 out of 7 mice, as
opposed to all other strains, which consistently produced OM in the femurs. In order to further
confirm the utility of BLI as a measure of OM, 15 BLI− hindlimbs from across all strains were
examined histologically, and all appeared normal, except for only one that had evidence of minor
inflammation in the joint space. We also examined 3 hindlimbs that were BLI+ at low levels for only
2 to 3 weeks out of the 5 weeks of imaging. These also all exhibited only low levels of inflammation
in the bone or joint but no bacterial colonies or well-formed abscesses.

FIG 5 Histological changes to hindlimbs with HOM. Each row depicts representative histology of the distal femur
and knee joint, with or without the proximal tibia, from three separate samples of mice injected with NRS384 (A to
C), LAC (D to F), TI1 (G to I), TI2 (J to L), or TI3 (M to O). In panels with both bones, the femur is on the left, and
the tibia is on the right. Symbols denote specific histological characteristics: *, abscess with visible bacterial
colonies; @, abscess without visible bacterial colonies; #, growth plate disruption; black arrows, inflammation within
the joint space and/or synovium; black arrowheads, infection focally extending from the joint into the bone. The box
in panel F depicts an area of higher magnification in Fig. 6C.

Focusing on OM lesions, higher-magnification images demonstrate characteristic abscesses
with neutrophil infiltration and large macrophages surrounding the lesions (Fig. 6A and B, black
arrowheads), some with central bacterial colonies (Fig. 6B, *). We observed only one example of a
sequestrum, in a tibia from a LAC infection (Fig. 5F, black box). In the higher-magnification image,
collections of cocci on the bone surface (Fig. 6C, black arrows) as well as empty lacunae can be
seen. Since we saw dramatic bone loss, we looked for osteoclasts (OCs) by staining for tartrateresistant acid phosphatase (TRAP) (an osteoclast marker), finding that many bone surfaces close
to abscesses were covered by these resorptive cells (Fig. 6D to I).

FIG 6 Detailed histological characteristics of HOM. (A and B) Abscesses without (@) (A) and with (*) (B) visible
bacterial colonies were surrounded by enlarged macrophages (black arrowheads). (C) Magnified image of the
sequestrum from Fig. 5F showing bacteria (black arrows). (D to I) TRAP staining (red) for osteoclast activity. Panels
G to I depict higher magnifications of the black boxes indicated in panels D to F, respectively. Scale bars are
presented for each row of images.

While it was not uncommon to find damage to the tibial epiphysis in cases with SA, an
involvement of the tibial metaphysis or diaphysis was rare in all strains used except for LAC. One

TI3-injected mouse had abscesses with bacterial colonies throughout the diaphyseal marrow
space and a focus of periosteal reaction surrounding an abscess that appears to be outside the
normal cortical shell (Fig. S7A). In addition to displaying markedly more tibial involvement than all
the other strains, LAC-injected mice also had two cases of inflammation with reactive bone
formation on the periosteal surface (Fig. S7B to D). In one case, the metaphysis of a tibia from a
TI2-injected mouse was fibrotic, with a rim of new bone formation, just distal to the growth plate
(Fig. S7E and F). While not prevalent, these instances of new bone formation provide further
evidence that our murine HOM model shares many features with the human disorder. Altogether,
this histology reveals significant pathological differences of OM infections between the clinical
isolates.
Varying effects of clinical isolates on osteoblasts and osteoclasts. Next, we investigated
whether these different strains exhibited virulence differences using our osteoclast intracellular
proliferation (29) and osteoblast cytotoxicity (16) assays. First, osteoclasts differentiated for 3 days
in culture were separately infected with each strain for 30 min, and all uninternalized bacteria were
then killed by the addition of antibiotic to the culture for 1 h. Osteoclasts were lysed immediately
thereafter (1.5 h postinfection), indicative of internalization, or cultured until 18 h postinfection, to
allow proliferation, and CFU were enumerated. TI2 produced a significantly lower increase in the
CFU between 1.5 and 18 h than all other strains (Fig. 7A). Input CFU and CFU measured 1.5 h
after infection were similar among all strains (Fig. S8A and B), indicating that the observed
difference in TI2 CFU at 18 h was related to decreased intracellular proliferation within osteoclasts
and not internalization. Next, cytotoxicity was assessed by adding concentrated bacterial
supernatants to cultured MC3T3 osteoblastic cells for 22 h (Fig. 7B). While all other strains
showed complete cytotoxicity with the addition of 10% supernatant, the TI2 supernatant had no
effect on osteoblast cell survival. LAC and TI3 were the most cytotoxic, with complete killing with
5% supernatant. Thus, the lower incidence of HOM with TI2, but not LAC, was associated with
decreased direct effects on bone cells. These data, in addition to our histology, further
characterize TI2 as functionally distinct from the other isolates.

FIG 7 Effects of S. aureus strains on bone cells in vitro. (A) Intracellular proliferation within cultured osteoclasts
measured by the change in CFU between 1.5 and 18 h postinfection. *, P ≤ 0.0015 compared to all other strains as
measured by one-way ANOVA with Tukey’s post hoc test. (B) MC3T3 survival after 22 h of exposure to medium
with either 5% or 10% concentrated S. aureus culture supernatant, relative to a medium-only control. Bars
represent the means, and error bars are SD (n = 10). # and @, P < 0.0001 compared to all other 5% supernatants;
*, P < 0.0001 compared to all other 10% supernatants (by two-way ANOVA with Tukey’s post hoc test).

Genetic sequence typing of the clinical isolates. In order to begin investigating the inherent
genetic differences underlying the observed differences in pathogenicity, the genomes of three
clinical isolates (TI1, TI2, and TI3) were sequenced, and multilocus sequence typing (MLST) was

performed as previously described (30). This analysis showed that TI2 belongs to clonal complex
5 (CC5), indicative of a USA100 clonal lineage, while TI1 and TI3 are both of CC ID8, consistent
with a USA300 clonal lineage (Fig. 8A). When each isolate was compared with its respective
clonal lineage reference strain (FPR3757 for USA300 and N315 for USA100), TI2 had more than
3 times the number of total polymorphisms, as well as genes containing at least one
polymorphism, detected compared to TI1 and TI3 (Fig. 8B and C). Next, 173 virulence-associated
genes within each isolate were grouped by function and examined for the presence of
polymorphisms, compared to their respective reference strains (31). TI2 shows more
polymorphisms in genes related to adhesins and immune evasion than Tl1 or TI3 (Fig. 8D and E;
Fig. S9, red squares). However, polymorphisms in the other categories were relatively infrequent
in all pediatric strains.

FIG 8 Genetic differences between clinical isolates of S. aureus. (A) Multilocus sequence typing (MLST) of the
clinical isolates (TI1, TI2, and TI3) and the reference strains NRS384 (USA300), FPR3757 (USA300), and N315
(USA100) listed with the allele identifiers (* denotes the closest match [no exact allele identification]) for each MLST
locus, clonal complex (CC), and strain type (ST). (B to E) Enumerated single nucleotide polymorphisms (SNPs)
compared to the reference strain (B), total number of genes with at least one SNP (C), and percentage of adhesin
genes (D) or immune evasion genes (E), as designated in Fig. S8 in the supplemental material, with at least one
SNP.

DISCUSSION
Using multiple clinical isolates of S. aureus from children with osteomyelitis as well as two
community-acquired strains from adult patients (NRS384 and LAC, originally isolated from skin
[32, 33]), we achieved reproducible development of HOM in mice. By generating stably
bioluminescent bacteria, we were able to track overt infection occurrence and location over time.
Important for their utility in the study of HOM, the strains and clinical isolates tested produced
frequent hindlimb infections that did not rely upon direct bone inoculation or prior bone
manipulation. Furthermore, mice did not become obviously septic immediately following injection
and mostly survived for the duration of the experiment, except for occasional hindlimb lameness or
paralysis necessitating euthanasia after several weeks. The ease of tracking, early onset of
infection, associated bone loss, and formation of characteristic abscesses all stand to make this a
very effective model for the further study of HOM pathogenesis. Because the BLI signal in bone
correlated well with the bacterial load, both in vivo and in vitro, destructive CFU assays are not
required to assess the effects of manipulations of either the host or pathogen on the bacterial

burden in this model, and the bacteria can be tracked longitudinally in each mouse. Additionally,
our HOM model mimics many of the hallmarks of juvenile HOM. Clinically, the most frequent site
of infection is the metaphysis of the femur or tibia (12), a trend recapitulated in our studies. We
also found several examples of abscesses located within the diaphysis of the femur and tibia,
although this was not found in the majority of samples. We observed rapid trabecular bone
destruction, as early as 2 weeks postinjection. However, significant cortical bone changes were
rare, with only a few examples of periosteal reactive bone formation along with one sequestrum.
These infections persisted over the duration of our 5-week follow-up, but longer periods of study
are warranted to fully characterize the chronic effects of these infections, as persistence and
recurrence are some of the most challenging aspects of treating HOM patients.
Both BLI and CFU assays support the primary sites of infection after intravenous inoculation of
all strains examined to be bone/joint and kidney/bladder. However, CFU assays also demonstrate
low, but detectable, levels of live bacteria in femurs without distinct foci of bioluminescence or
histological changes such as abscess formation. Interestingly, in mice inoculated with the pediatric
isolates, these BLI− femurs had trabecular bone volumes that were higher than those of the BLI+
femurs but lower than those of control noninjected mice. The lack of bone volume differences
between BLI+ and BLI− femurs in NRS384- and LAC-injected mice may indicate a limitation of BLI
in predicting bone loss, but this could also indicate inherent differences in the abilities of certain
strains to cause bone loss. Additionally, the presence of measurable bacteria within BLI− bones
could suggest a limitation in the sensitivity of BLI as a readout for infection. However, most of the
BLI− hindlimbs appeared completely normal by histology, with only 1 having signs of minor
inflammation. Also, all samples from mice where low-level BLI positivity at early time points
resolved, falling below our BLI threshold before the end of imaging, showed only low levels of
inflammation but not abscesses or bacterial colonies. Thus, assessment of BLI over time
correlates well with both the bacterial load and the histological features of OM, although latent
bacteria present in bone are not detected by either BLI or standard histology. Ultimately, more
detailed assessments, including examination of other skeletal sites and imaging of bacteria in situ
at high resolution, are needed to determine whether bone loss at BLI-negative sites is driven by
systemic inflammation, direct effects of sparsely distributed bacteria in bone, or a combination of
both.
Interestingly, by using multiple clinical isolates of S. aureus, we found overt differences in their
pathogenicities ranging from infection incidence to predilection toward specific infection types
(osteomyelitis versus septic arthritis). There were also more subtle differences between the
isolates, such as the intensity of the BLI signal in the BLI+ legs and the lesser drop in the bone
volume of IT2-injected mice than for the other two isolates, although this could be a consequence
of the lower percentage of bone-centered infections, as we were able to use microCT to analyze
only two BLI+ legs. LAC also produced relatively few HOM infections, but those that occurred
tended to involve the tibia rather than the femur. However, only TI2, and not LAC, displayed lower
osteoblast cytotoxicity and intraosteoclast proliferation. These findings coincide with previous work
establishing that S. aureus clinical isolates differ in their virulence, pathogenicity, and toxicity and
that lower cytotoxicity correlates with increased persistence in vivo (34, 35). We found major
differences in specific tissue tropisms among isolates. TI2 displayed a predilection toward
promoting SA compared to the other strains, especially TI3, while LAC predominantly targeted the
tibia over the femur. However, our knowledge of the clinical behavior of these isolates is limited to
only one patient per isolate, so it is currently unclear how these findings translate to a broader
population. Further work is needed to determine specific bacterial factors that may promote
differences in infection incidence and tropism as well as if the lower cytotoxicity of TI2 contributes

to chronicity as seen with other isolates (34, 35). It will be interesting to see if the incidence of
sequestra or periosteal reactions, characteristic changes of chronic osteomyelitis, increases over
time past the 5 weeks that we examined here.
Using genomic sequencing of the new clinical isolates, we have begun to explore how genomic
content shapes the observed clinical differences. When the isolates were sequence typed, the TI2
isolate was shown to be of the USA100 clonal lineage, whereas the other isolates were of the
USA300 lineage. USA100 has a higher prevalence in hospital-acquired infections, while USA300
predominates in community-acquired infections (36, 37). While none of the patients from whom
these isolates were taken had hospital-acquired infections, a family member of the TI2 isolate
patient was reported to be a health care worker. Although we do not yet know the traits of TI2 that
underlie its pathogenic characteristics, this study highlights the importance of examining strains of
other lineages besides USA300 as they are still circulating, are able to cause OM and SA, and
could have differences in their pathogenicities. Sequencing these isolates is the first step in
understanding these differences and gives us a resource to identify other genetically related
strains. TI2 was found to have a number of polymorphisms in specific genes related to adhesins
and immune evasion. This could explain the lower infection incidence as both surface adhesion
and the ability to evade immune destruction are critical steps in infection initiation and
propagation. Also, differences in adhesin expression may help explain the predilection of TI2 to
promote SA as opposed to OM. Despite the different clades, TI2 and LAC have similar overall
infection incidences in our model. However, LAC displayed osteoblast cytotoxicity and
intraosteoclast proliferation similar to those of the other USA300 strains, whereas strain TI2 was
significantly less cytotoxic. These results, taken together with infection incidence differences,
suggest that the strain of bacteria could be important to note when comparing results from
different models of osteomyelitis.
It is apparent in our study that many mice in our model develop kidney infections as well as OM
in long bones, so it is difficult to determine with certainty whether OM is primary or secondary.
However, some mice develop infections only in the tibia or femur, suggesting this to be the primary
infection location, and we have not seen any examples of mice that develop OM after first having
a kidney/bladder infection identified by BLI. Another limitation is that our study has focused only on
MRSA isolates. Methicillin-susceptible strains of S. aureus are also a significant cause of hospitaland community-acquired infections, which will require investigation. Also, this study utilized only
male mice in order to minimize variations between cohorts, as we were primarily interested in
elucidating differences between the strains of S. aureus used. In the future, studies to determine
host-specific influences, including sex differences, on HOM development and progression will
need to be performed in order to assess the generalizability of this model.
Ultimately, our work demonstrates that HOM can be reproducibly initiated in immunocompetent
mice using clinical isolates and that utilizing multiple isolates is likely necessary to capture the
range of human diseases. This panel of bioluminescent strains will be critical for further studies to
elucidate biological mechanisms underpinning pediatric HOM development and propagation,
eventually aiding in more efficacious clinical treatments and therapies.
MATERIALS AND METHODS
Animals. For these studies, we used 6-week-old male C57BL/6 mice, with a mutation in the
tyrosinase gene [B-6 albino; B6(Cg)-Tyrc-2J/J; Lane, 1973] (JAX stock number 000058; The
Jackson Laboratory, Bar Harbor, ME) (38) that renders their fur albino and allows improved
bioluminescence imaging. For hematogenous osteomyelitis modeling, 2.5 × 106 bacteria were
injected in 100 μl of PBS via the tail vein. Control, noninjected mice used for microCT analysis

were age and sex matched. Mice were housed 5 per cage with food and water ad libitum and
closely monitored throughout the experiments for signs of morbidity until they were humanely
euthanized by asphyxiation with CO2.
Clinical isolates. Clinical isolates were obtained from the St. Louis Children’s Hospital and
Barnes Jewish Hospital clinical microbiology laboratories by Stephanie A. Fritz and transferred to
Deborah J. Veis in accordance with Washington University Institutional Review Board approval
(IRB number 201805091). None of the patients required pediatric intensive care unit admission or
intubation. Antibiotic susceptibility profiles can be found in Table 3.

Bacterial growth and preparation of inocula. All strains of S. aureus were routinely grown on
tryptic soy agar (TSA) or in tryptic soy broth (TSB) (Fisher Scientific, Hampton, NH) at 1:200 with
shaking at 220 rpm overnight and subcultured at 1:100 for 2 h before injection. Bacteria were
subsequently pelleted and resuspended in PBS to a final optical density at 600 nm (OD600) of 1.
Injections were prepared by further dilution of bacteria in PBS to a final count of 2.5 × 106 bacteria
in 100 μl of PBS.
The NRS384 S. aureus strain used was already stably bioluminescent (27). The LAC strain of
S. aureus used was a dual-fluorescence luminescent strain of S. aureus. To generate the dualfluorescence luminescent strain of S. aureus, the attC::PsarA-sodRBS-mCherry allele from S.
aureus LAC (a gift from Victor Torres) was first cloned into PJC1306 (39) using Gibson assembly.
PJC1306 containing this allele was electroporated into RN9011 and integrated into the genome
with tetracycline selection for successful integration. The attC::PsarA-sodRBS-mCherry allele was
transduced with phi-85 into an erythromycin-sensitized USA300 lineage S. aureus strain, AH1263
(28). Next, the construct PgapA-luxBADCE was transduced with phi-85 into LAC attC::PsarAsodRBS-mCherry.
In order to produce stable bioluminescence in the clinical isolates, electrocompetent cells of
each isolate were prepared and electroporated with the pRP1195 plasmid, as previously described
(27). Clones containing the plasmid were selected for by chloramphenicol resistance and
bioluminescence. Plasmid integration was then driven by a temperature shift to 43°C for 6 to 7 h,
as previously described (27), after which bacteria were serially diluted onto TSA plates containing
5 μg/ml and grown at 43°C overnight. Clones with bioluminescence were again selected, and 20%
glycerol stocks were made.
Planktonic growth assay. Bacteria were streaked onto TSA plates and grown at 37°C
overnight. Single colonies from clinical isolates were selected and cultured in TSB with shaking at
220 rpm overnight at 37°C. The culture grown overnight was then diluted in TSB at 1:100 in fresh
TSB. The OD600 was measured every 30 min for 5 h.
Bioluminescence imaging. In vivo bioluminescence imaging was performed on an Ivis 50
instrument (Living Image 4.3.1; PerkinElmer, Waltham, MA) using a 1-min exposure, bin 8, Field of
View (FOV)12cm, Focal length (f/stop)1, and open filter. Mice were imaged under isoflurane

anesthesia (2% vaporized in O2). Bacterial cultures grown in vitro were imaged using the same
Ivis 50 instrument, using a 1-s exposure, bin 8, FOV12cm, f/stop1, and open filter. The total
photon flux (photons per second) was measured from fixed regions of interest (ROIs) set over the
hindlimbs, as depicted in Fig. S2 in the supplemental material, or from individual wells using Living
Image 2.6.
Micro-computed tomography analysis. Hindlimb bones were fixed for 48 h in 10% neutral
buffered formalin and then stored in 70% ethanol. Bones were scanned ex vivo using a μCT40
instrument (Scanco Medical, Switzerland) (10 μm, 55 kilovoltage peak (kVp), 145 μA, 8 W, and
300-ms integration time) and analyzed with μCT Evaluation Program V6.6. For trabecular bone
analyses, regions of interest were defined as 100 slices below the femoral growth plate. Outcome
variables are reported in accordance with published consensus guidelines (40). Mice sacrificed
earlier than the desired endpoint were not included in the micro-computed tomography (microCT)
analysis.
Histology. After microCT analysis was performed, bones were decalcified for 14 days in 14%
EDTA-free acid and then stored in 70% ethanol. For tissue processing and staining, samples were
submitted to the Washington University Musculoskeletal Histology and Morphometry Core for
hematoxylin and eosin (H&E) or tartrate-resistant acid phosphatase (TRAP) staining. Two to three
sections were examined per mouse. Images were taken using an Olympus BX-51 microscope
equipped with an Olympus DP27 camera and cellSens Standard software.
Enumeration of CFU. At 3 weeks postinjection, tissues were harvested using a Bullet-Blender
and Navy lysis tubes (Next Advance, Inc., Averill Park, NY) at 4°C. To enumerate bacterial CFU,
the whole organ (tibia, femur, heart, kidney, or liver) was homogenized in TSB, serially diluted in
TSB, and plated on TSA plates at 37°C overnight for bacterial colony enumeration.
Intracellular proliferation assay. Osteoclasts (OCs) were generated from enriched bone
marrow macrophages (BMMs) harvested from the long bones of 10- to 12-week-old wild-type
C57BL/6 mice and cultured in alpha-minimal essential medium (MEM) with 10% fetal bovine
serum (FBS) and a 1:10 dilution of the CMG 14-12 cell supernatant (containing the equivalent of
100 ng/ml of macrophage colony-stimulating factor [M-CSF]) for 4 days to expand BMMs. BMMs
were seeded into 12-well tissue culture-treated plates at 1.5 × 105 cells per well and differentiated
into OCs for 3 days in alpha-MEM with 10% FBS, a 1:50 dilution of the CMG 14-12 cell
supernatant (20 ng/ml M-CSF), and 60 ng/ml GST (glutathione S-transferase)-Receptor activator
of nuclear factor kappa-B ligand (RANKL).
CFU were enumerated after a gentamicin protection assay, as previously described (29).
Briefly, OCs were infected with S. aureus strains at a multiplicity of infection (MOI) of 10:1 for 30
min. Cells were then washed with PBS and cultured in medium containing antibiotic (0.3 mg/ml
gentamicin) for 1 h to kill extracellular bacteria. Next, cells were again washed in PBS, and cells at
the 1.5-h time point were lysed in sterile, cold, molecular-grade H2O. Cells at the 18-h time point
were replenished with medium with M-CSF and RANKL until hypotonic lysis, as described above.
Lysates were 10-fold serially diluted and plated on TSA plates for incubation overnight at 37°C.
S. aureus culture supernatant concentration. Three colonies from each S. aureus strain
were inoculated into 50 ml of RPMI 1640 supplemented with 1% Casamino Acids in a 250-ml
Erlenmeyer flask. Flasks were stoppered and incubated at 37°C with shaking at 180 rpm for 15 h.
Bacterial cultures were centrifuged at 4,000 × g for 10 min at 4°C, and culture supernatants were
removed and filter sterilized using a 0.22-μm filter. The supernatants were concentrated with an
Amicon Ultra 3-kDa nominal molecular weight limit centrifugal filter unit (Millipore), according to
the manufacturer’s instructions. Concentrated supernatants were filter sterilized again with a 0.22μm filter, and aliquots of each supernatant were stored at −80°C until use in the cytotoxicity assay.

Cytotoxicity assay. MC3T3-E1 cells obtained from the American Type Culture Collection
(ATCC) were propagated according to ATCC recommendations. Cells were grown at 37°C with
5% CO2, with replacement of the medium every 2 to 3 days. For cytotoxicity assays, MC3T3 cells
were seeded in 96-well tissue culture plates at a density of 5,000 cells in 200 μl medium per well.
After 24 h, the medium was removed, and fresh medium containing either 5% or 10%
concentrated S. aureus culture supernatant or RPMI 1640 was added to the cell monolayers. The
MC3T3 cells were incubated for an additional 22 h, and cell viability was then assayed using a
CellTiter 96 AQueous one solution cell proliferation assay (Promega), according to the
manufacturer’s instructions. Survival was calculated for MC3T3 cells exposed to each supernatant
condition as a percentage of survival relative to MC3T3 cells exposed to medium containing RPMI
1640.
S. aureus clinical isolate sequencing. DNA was isolated from bacterial cultures grown
overnight using the DNeasy blood and tissue kit (catalog number 69504; Qiagen) according to the
manufacturer’s instructions. Whole-genome sequencing was performed at the Genome
Technology Access Center at the Washington University in St. Louis School of Medicine using an
Illumina NovaSeq 6000 instrument with an S4 flow cell and 2-by-150 paired-end reads. Sequence
reads were aligned to the reference genome using NovoAlign. USA300_FPR3757 (NCBI
accession number NC_007793.1) was used for the USA300 reference genome, and N315 (NCBI
accession number BA000018.3) was used for the USA100 reference genome. The alignments
were sorted with SAMtools. Picard Tools was used to remove duplicate reads. Variant files and
BAM alignments for each clinical isolate were analyzed using Geneious Prime v. 2021.0.1.
Statistical analysis. All data are represented as means with standard deviations (SD). All data
were analyzed by one-way analysis of variance (ANOVA) with Tukey’s multiple-comparison post
hoc test (GraphPad InStat), except for correlation data, where the Pearson correlation coefficient
was calculated, and Fig. 4A, where differences between BLI− and BLI+ legs for each isolate were
calculated by Student’s t test (GraphPad InStat). A P value of <0.05 was taken as significant.
Ethics statement. All animal procedures were approved by the Institutional Animal Care and
Use Committee of Washington University (IACUC protocols 20170025 and 19-1059), according to
established federal and state policies outlined in the Animal Welfare Act (AWA) and enforced by
the U.S. Department of Agriculture (USDA), Animal and Plant Health Inspection Service (APHIS),
USDA Animal Care. Clinical isolates were obtained under Washington University Institutional
Review Board approval (IRB number 201805091).
Data availability. Genomic sequences for TI1 (NCBI accession number SRX11116571), TI2
(NCBI accession number SRX11116572), and TI3 (NCBI accession number SRX11116573) are
available at the NCBI Sequence Read Archive.
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